© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
June 07, 2010
Researchers at Children's Hospital Boston say that they have
developed the first oral, broad-spectrum angiogenesis inhibitor that
may offer a potential nontoxic therapy for a wide range of cancers. The drug was formulated through nanotechnology and has shown promising anticancer results in mice.
High Relapse Rate After Discontinuing Antiviral Therapy for HBV Patients With Cirrhosis
Insomnia, Hypersomnia Identified as Symptoms of Long COVID Syndrome
Study Evaluates Insomnia and Suicidality Among Healthcare Workers During COVID-19 Pandemic